Contact Us | Search | Site Map
Crucell
Bringing Innovation to Global Health
  About Us 
   Crucell at a Glance
   Our History
   Mission & Strategy
   Guiding Principles
   Crucell Worldwide
   Management
   Corporate Governance
  Technology 
   PER.C6® Technology
   Vaccine Technology
   Protein Technology
  Products 
   Quinvaxem®
   Hepavax-Gene®
   MoRu-Viraten®
   Epaxal®
   Vivotif®
   Dukoral®
   Inflexal® V
   Questions About Products
  R&D 
   Development Programs
   Clinical Trials
   Scientific Publications
  Partners 
   Strategic Partners
   Marketing & Sales Partners
   R&D Partners & Licensees
   Partnering Opportunities
  Investors 
   Corporate Profile
   Share Information
   Financial Information
   Press Releases
   Event Calendar
   Presentations
   Shareholder Services
   Investor Relations Contacts
  Media 
   Press Releases
   Media Kit
   Image Library
   Useful Links
   Glossary
   Media Contacts
  Careers 
   Vacancies
   Internships
   Benefits & Rewards
   Our Team
  Hidden 
   10 year anniversary Inflexal V

Stock Quotes:
Euronext: €
NASDAQ: $
SWX: CHF
10.69 -0.05 (15 minute delay)
15.30 0.00 (15 minute delay)
17.60 0.00 (15 minute delay)
More information on our share performance
Crucell focuses on the development, production and marketing of vaccines and antibodies against infectious disease worldwide. Through our portfolio of core marketed vaccines, we have established markets in hepatitis B, pediatric, respiratory and travel vaccines.
Annual General Meeting of Shareholders 2008
Friday 30 May 2008, 14:00 CET - Hooglandse kerk Leiden
More information
MoveNext - Latus © Crucell 2006 | Disclaimer